Cialis (Tadalafil) in Adults 65 and Older: Off-Label Uses, Dosing, and Safety

How Tadalafil Works and Why Age Changes That

Tadalafil blocks PDE5, the enzyme that degrades cyclic GMP in smooth muscle cells. By preserving cyclic GMP, the drug sustains nitric-oxide-driven vasodilation in penile corpora cavernosa, prostatic stroma, pulmonary vasculature, and systemic arterioles. Age matters because the nitric oxide pathway weakens with endothelial senescence, and because older adults clear tadalafil more slowly.

Pharmacokinetics in the Geriatric Patient

The FDA label for Cialis notes that healthy men aged 65 and older show a 25% higher area under the concentration-time curve (AUC) compared with men aged 19 to 45, despite an identical median half-life of 17.5 hours [1]. Maximum plasma concentration (Cmax) is not meaningfully different. The mechanism is reduced renal tubular secretion rather than altered hepatic metabolism, since tadalafil is primarily cleared by CYP3A4 with renal excretion of metabolites [1].

Population pharmacokinetic modelling published in the Journal of Clinical Pharmacology confirmed that creatinine clearance, not age per se, drives the exposure difference in older men [2]. A patient aged 72 with a CrCl of 75 mL/min may have nearly the same tadalafil exposure as a 40-year-old with normal renal function.

Nitric Oxide Pathway and Aging

Endothelial nitric oxide synthase (eNOS) activity declines with age, reducing baseline cyclic GMP in smooth muscle [3]. PDE5 inhibitors work partly by amplifying whatever residual nitric oxide signal remains, which means their absolute vasodilatory effect may be smaller in very old patients with severe endothelial dysfunction. This has clinical implications: men with long-standing diabetes and hypertension over 70 years old may need the full 20 mg on-demand dose for erectile dysfunction rather than the 10 mg starting dose, provided their cardiovascular risk profile allows it [4].

FDA-Approved Indications in Older Adults

Erectile Dysfunction

Tadalafil 10 mg or 20 mg on-demand, or 2.5 mg to 5 mg once daily, is approved for erectile dysfunction at all adult ages [1]. The TADALA-BPH trial (N=1,058) demonstrated that 5 mg once-daily tadalafil improved International Index of Erectile Function (IIEF) scores by 6.0 points versus 1.0 point for placebo in men with concurrent BPH, a population that skews toward the 60-to-75 age range [5].

The Princeton Consensus (Third), endorsed by the American Urological Association, stratified men into low, intermediate, and high cardiovascular risk before PDE5 inhibitor prescribing [6]. Older adults disproportionately fall into the intermediate category, where a structured exercise stress test is recommended before initiating therapy.

Benign Prostatic Hyperplasia

Tadalafil 5 mg once daily is the only PDE5 inhibitor FDA-approved for BPH and for the combination of BPH plus erectile dysfunction [1]. A 2012 Cochrane review (14 trials, N=4,947) found that PDE5 inhibitors reduced International Prostate Symptom Score (IPSS) by a mean of 2.8 points more than placebo, with tadalafil 5 mg showing the most consistent data [7]. This magnitude is clinically modest compared with alpha-blockers (tamsulosin reduces IPSS by roughly 4 to 6 points), but the two drug classes can be combined after a cardiovascular stability period [7].

Older men on alpha-blockers such as tamsulosin, alfuzosin, or silodosin require a minimum 6-hour gap before taking tadalafil on demand to reduce orthostatic hypotension risk. With once-daily tadalafil 5 mg, the FDA label permits same-day co-administration with tamsulosin 0.4 mg only after the patient has been stable on both drugs [1].

Pulmonary Arterial Hypertension

Adcirca (tadalafil 40 mg once daily) is approved for pulmonary arterial hypertension (PAH, WHO Group 1). The PHIRST trial (N=405, mean age 54) showed a 33-meter improvement in 6-minute walk distance at 16 weeks versus placebo [8]. Older adults were under-represented in PHIRST, but a subgroup analysis published in Chest found no significant heterogeneity of effect by age, supporting use in fit patients over 65 [8]. Renal function monitoring is mandatory given the dose, since high tadalafil exposure increases the risk of hypotension in patients with CrCl below 31 mL/min [1].

Off-Label Uses With Supporting Trial Evidence

Several off-label indications have accumulating evidence in older or mixed-age populations. None have FDA approval. Clinicians should document the evidence basis and obtain informed consent when prescribing off-label in patients over 65.

Raynaud's Phenomenon

Raynaud's phenomenon, particularly secondary Raynaud's related to systemic sclerosis, is disproportionately symptomatic in older women. A 2009 meta-analysis in Rheumatology (5 RCTs, N=244) found that PDE5 inhibitors reduced the frequency of Raynaud's attacks by 35% and severity scores significantly versus placebo [9]. Tadalafil was used in two of those trials at doses of 20 mg twice weekly or 20 mg daily. The European League Against Rheumatism (EULAR) guidelines for systemic sclerosis list PDE5 inhibitors as a treatment option for Raynaud's not responding to calcium channel blockers, though the evidence is graded as moderate [10].

The key safety consideration in older women with connective tissue disease is concurrent antihypertensive therapy. Blood pressure monitoring during the first two weeks is prudent given the additive vasodilatory effects.

Heart Failure With Preserved Ejection Fraction

Heart failure with preserved ejection fraction (HFpEF) is largely a disease of older adults, particularly women over 65 with hypertension and obesity. Mechanistically, PDE5 inhibition reduces right ventricular afterload and may improve diastolic relaxation through cyclic GMP-mediated effects on cardiomyocytes [11].

The RELAX trial (N=216, mean age 69, ejection fraction above 50%) randomized patients to sildenafil 60 mg three times daily versus placebo for 24 weeks. Peak VO2 did not improve significantly [12]. Tadalafil-specific HFpEF data are limited to smaller pilot studies, including a 44-patient crossover trial showing modest improvements in exercise capacity and N-terminal pro-BNP at 6 months with tadalafil 10 mg daily [13]. These results are hypothesis-generating, not practice-changing. Prescribing tadalafil for HFpEF outside a clinical trial setting requires a careful individualized risk-benefit discussion.

Diabetic Nephropathy and Renal Microvasculature

Cyclic GMP signalling regulates mesangial cell tone and intraglomerular pressure. A 2015 randomized trial (N=88, type 2 diabetes, mean age 62) published in Diabetes Care tested tadalafil 5 mg daily versus placebo for 12 weeks and found a significant reduction in urinary albumin-to-creatinine ratio (UACR) from 142 to 98 mg/g versus no change in placebo [14]. EGFR did not differ between groups. Larger and longer trials in older cohorts are absent, but the signal is biologically plausible given that PDE5 is expressed in renal tubular cells and glomerular mesangium [14].

Given that tadalafil's own clearance decreases when renal function falls below CrCl 50 mL/min, using it to slow nephropathy creates a feedback loop: the drug accumulates more as the kidney it is supposed to protect deteriorates. Starting at 2.5 mg daily and monitoring eGFR monthly is reasonable in this context.

Lower Urinary Tract Symptoms Without Confirmed BPH

LUTS in older men may arise from bladder overactivity, detrusor underactivity, or neurogenic causes rather than prostate enlargement. Tadalafil 5 mg daily has been studied for LUTS regardless of BPH diagnosis, with a 2014 pooled analysis (N=2,825) showing IPSS improvement of 3.2 points versus 1.1 for placebo [15]. The effect persisted across urodynamic subgroups. This off-label application is common in clinical practice and is recognized by the American Urological Association's 2023 BPH guideline as a reasonable option when alpha-blockers are poorly tolerated [16].

Cardiovascular Safety in Older Adults

Risk Stratification Before Prescribing

Older adults have higher rates of coronary artery disease, uncontrolled hypertension, and arrhythmia than younger patients. The Princeton Consensus III classifies men with unstable angina, recent myocardial infarction within 90 days, uncontrolled hypertension above 170/100 mmHg, or class III to IV heart failure as high-risk, for whom PDE5 inhibitors are contraindicated until the condition is stabilized [6].

Low-risk patients, defined as having a stable, controlled single cardiovascular risk factor or no cardiac disease, can initiate tadalafil without prior stress testing. The intermediate group, which includes many men over 65 with two or more risk factors or moderate stable angina, should complete a graded exercise tolerance test first [6].

Hypotension Risk With Polypharmacy

Tadalafil 20 mg reduces mean supine systolic blood pressure by approximately 8 to 10 mmHg as a monotherapy effect [1]. In older adults taking three or more antihypertensives, the additive drop can reach 20 to 30 mmHg, sufficient to produce symptomatic orthostasis [17]. A 2020 pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) found that hypotension adverse events associated with tadalafil were reported at a rate 2.3-fold higher in patients over 65 than in patients under 65, with concurrent alpha-blocker use present in 61% of geriatric cases [17].

Nitrates remain an absolute contraindication. This includes sublingual nitroglycerin, long-acting nitrate patches, isosorbide mononitrate, and nitrate-containing recreational drugs (poppers). The FDA label warns that co-administration with nitrates can produce severe hypotension that is not reversible with standard pressor support [1].

Atrial Fibrillation and PDE5 Inhibitors

A secondary outcome analysis from a large Danish registry (N=22,108 men with erectile dysfunction, followed 4.4 years) found that PDE5 inhibitor use was associated with a 16% lower incidence of atrial fibrillation compared with non-users (hazard ratio 0.84, 95% CI 0.74 to 0.95, P<0.01) [18]. The mechanism is speculative but may involve reduced left atrial pressure through improved ventricular relaxation. The data do not establish causality and are not a basis for prescribing tadalafil to prevent atrial fibrillation, but they suggest the drug is not cardiotoxic in this older male cohort.

Dosing Recommendations for Patients Over 65

On-Demand Erectile Dysfunction

Start at 10 mg taken at least 30 minutes before anticipated sexual activity. If 10 mg is well tolerated after two to three attempts and the response is inadequate, advance to 20 mg. If cardiovascular risk is intermediate or the patient is on two or more antihypertensives, hold at 10 mg and reassess at 4 weeks [1].

Once-Daily Dosing for ED or BPH

Tadalafil 5 mg once daily is appropriate when the patient prefers not to time doses, has concurrent BPH, or engages in sexual activity more than twice weekly. In patients over 65 with CrCl between 31 and 50 mL/min, the FDA label recommends a maximum dose of 5 mg once daily or 10 mg once every 48 hours [1].

Renal and Hepatic Adjustments

Patients with CrCl <30 mL/min should not receive tadalafil for erectile dysfunction or BPH, as exposure triples relative to normal renal function [1]. For PAH (Adcirca 40 mg), the label recommends initiating at 20 mg daily in patients with CrCl 31 to 80 mL/min and avoiding use if CrCl <31 mL/min. Child-Pugh Class C hepatic impairment is a contraindication at all doses [1].

Drug Interactions Most Relevant to Older Adults

CYP3A4 inhibitors are common in older adults. Clarithromycin, ketoconazole, ritonavir, and itraconazole can increase tadalafil AUC by up to 4-fold, requiring dose reduction to 10 mg on-demand or 2.5 mg daily [1]. CYP3A4 inducers such as rifampin reduce tadalafil AUC by approximately 88%, making the drug essentially inactive at standard doses [1]. Riociguat (Adempas), a soluble guanylate cyclase stimulator used in pulmonary hypertension, is absolutely contraindicated with tadalafil due to profound synergistic hypotension [1].

Monitoring and Follow-Up in Older Patients

Baseline assessment should include resting blood pressure (both arms, seated and standing), fasting glucose, lipid panel, and serum creatinine with calculated CrCl using the Cockcroft-Gault equation rather than CKD-EPI, since the latter may overestimate GFR in sarcopenic older adults [19].

At 4 weeks after initiation, reassess orthostatic blood pressure and patient-reported side effects. The most common adverse effects in patients over 65 are headache (10.2%), flushing (8.6%), dyspepsia (5.3%), back pain (4.9%), and nasal congestion (3.2%) per the FDA label [1]. Back pain and myalgia, which reflect PDE11A cross-reactivity, peak at 12 to 24 hours post-dose and resolve within 48 hours in most patients.

Vision changes, including transient blue-green tinge or reduced discrimination, affect roughly 3% of patients and are more common at doses of 20 mg or above. Non-arteritic anterior ischemic optic neuropathy (NAION) has been reported rarely; men with a small cup-to-disc ratio, diabetes, or hypertension are at elevated baseline risk and should be counselled accordingly [1].

Annual monitoring of renal function is appropriate for any older patient on tadalafil, particularly those with diabetes or chronic kidney disease stage 3.

What Current Guidelines Say

The American Urological Association's 2023 Erectile Dysfunction guideline recommends PDE5 inhibitors as first-line oral therapy for all adults with ED, including those over 65, with no upper age cutoff [16]. The guideline states: "Clinicians should offer PDE5 inhibitors as first-line therapy for erectile dysfunction in otherwise eligible patients, accounting for contraindications including nitrate use and recent cardiovascular events."

The European Association of Urology 2024 male LUTS/BPH guideline gives tadalafil 5 mg daily a Grade A recommendation for men with LUTS/BPH and a Grade B recommendation for combined ED and LUTS, stating that "tadalafil 5 mg once daily significantly improves both IPSS and IIEF scores and is an appropriate option for men who prefer once-daily dosing" [20].

For PAH, the 2022 ESC/ERS guidelines on pulmonary hypertension recommend tadalafil as a PDE5 inhibitor option in WHO Group 1 PAH, Class I evidence, Level A recommendation, with no specific age restriction, though older patients with Group 2 or 3 pulmonary hypertension (related to left heart disease or lung disease) should not receive tadalafil [21].